Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
This article was originally published in The Pink Sheet Daily
University of Kentucky study showed lower dose submitted in Rx-to-OTC switch NDA led to 5% loss from baseline weight, carried similar adverse effect profile to Rx dose.
You may also be interested in...
Abuse was “extremely low” Glaxo researchers report at Vancouver meeting of the Obesity Society. Three-month, pharmacy-based trial offered 60 mg orlistat over-the-counter to consumers 18 and older.
FDA’s delays in implementing the Food Safety Modernization Act violated FSMA and the Administrative Procedures Act, a federal court finds in an April 22 order. The agency must meet with plaintiff Center for Food Safety to agree on new implementation deadlines by May 20.